$5.34
-0.20-3.61%
Last update: Nov 9, 4:24 AM
Bioage Labs Inc (BIOA) Stock Price, Quote, News & History
BIOANASDAQ
BioAge Labs stock plummeted as failed Phase 3 ZEUS trial data from Novo Nordisk sparked broad concerns for NLRP3-targeting therapies.
You can purchase shares of Bioage Labs (NASDAQ:BIOA) through any online brokerage.
Other companies in Bioage Labs’s space includes: Eli Lilly and Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co Inc (NYSE:MRK), Novartis AG (NYSE:NVS) and AstraZeneca PLC (NYSE:AZN).
Bioage Labs has a consensus price target of $40.78.
The stock price for Bioage Labs (NASDAQ: BIOA) is $5.48 last updated November 9, 2026 at 4:24 AM EST.
There are no upcoming dividends for Bioage Labs.
Bioage Labs does not have any upcoming earnings scheduled.
There is no upcoming split for Bioage Labs.
Bioage Labs is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The company's technology platform and differentiated human datasets enable the...
